HomeCompareQLI vs PLD

QLI vs PLD: Dividend Comparison 2026

QLI yields 36.97% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QLI wins by $7797498272.31M in total portfolio value
10 years
QLI
QLI
● Live price
36.97%
Share price
$5.41
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7797498278.82M
Annual income
$7,757,188,590,538,824.00
Full QLI calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — QLI vs PLD

📍 QLI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQLIPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QLI + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QLI pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QLI
Annual income on $10K today (after 15% tax)
$3,142.33/yr
After 10yr DRIP, annual income (after tax)
$6,593,610,301,958,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, QLI beats the other by $6,593,610,297,490,029.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QLI + PLD for your $10,000?

QLI: 50%PLD: 50%
100% PLD50/50100% QLI
Portfolio after 10yr
$3898749142.66M
Annual income
$3,878,594,297,897,630.00/yr
Blended yield
99.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

QLI
No analyst data
Altman Z
6.4
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QLI buys
0
PLD buys
0
No recent congressional trades found for QLI or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQLIPLD
Forward yield36.97%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%74.4%
Portfolio after 10y$7797498278.82M$6.50M
Annual income after 10y$7,757,188,590,538,824.00$5,256,436.18
Total dividends collected$7794837080.52M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: QLI vs PLD ($10,000, DRIP)

YearQLI PortfolioQLI Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$18,094$7,393.72$11,255$555.24+$6.8KQLI
2$44,366$25,005.57$13,062$1,018.59+$31.3KQLI
3$162,077$114,605.09$15,903$1,926.67+$146.2KQLI
4$955,989$782,566.99$20,839$3,823.32+$935.1KQLI
5$9,650,716$8,627,807.42$30,464$8,166.08+$9.62MQLI
6$173,125,864$162,799,598.80$52,054$19,457.30+$173.07MQLI
7$5,644,105,084$5,458,860,409.25$109,886$54,188.93+$5644.00MQLI
8$338,684,455,283$332,645,262,843.05$304,030$186,451.18+$338684.15MQLI
9$37,672,605,865,602$37,310,213,498,449.27$1,166,125$840,813.32+$37672604.70MQLI
10$7,797,498,278,815,018$7,757,188,590,538,824.00$6,504,190$5,256,436.18+$7797498272.31MQLI

QLI vs PLD: Complete Analysis 2026

QLIStock

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Full QLI Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this QLI vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QLI vs SCHDQLI vs JEPIQLI vs OQLI vs KOQLI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.